MX2019014026A - Metodos para la deteccion de melanoma. - Google Patents

Metodos para la deteccion de melanoma.

Info

Publication number
MX2019014026A
MX2019014026A MX2019014026A MX2019014026A MX2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A
Authority
MX
Mexico
Prior art keywords
methods
melanoma
melanoma detection
subject
detection
Prior art date
Application number
MX2019014026A
Other languages
English (en)
Spanish (es)
Inventor
Mark Kidd
Irvin Modlin
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of MX2019014026A publication Critical patent/MX2019014026A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
MX2019014026A 2017-05-25 2018-05-21 Metodos para la deteccion de melanoma. MX2019014026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (1)

Publication Number Publication Date
MX2019014026A true MX2019014026A (es) 2020-08-03

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014026A MX2019014026A (es) 2017-05-25 2018-05-21 Metodos para la deteccion de melanoma.

Country Status (14)

Country Link
US (2) US20180340934A1 (https=)
EP (1) EP3631017B1 (https=)
JP (1) JP7227964B2 (https=)
KR (1) KR102763004B1 (https=)
CN (1) CN111315897B (https=)
AU (1) AU2018273844B2 (https=)
BR (1) BR112019024481A2 (https=)
CA (1) CA3064732A1 (https=)
DK (1) DK3631017T3 (https=)
ES (1) ES2920288T3 (https=)
IL (1) IL270787B2 (https=)
MX (1) MX2019014026A (https=)
PL (1) PL3631017T3 (https=)
WO (1) WO2018217627A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838732A4 (en) * 2005-01-07 2010-07-14 Univ Johns Hopkins BIOMARKER FOR MELANOME
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
AU2007347118B2 (en) * 2006-11-03 2012-11-01 Baylor Research Institute Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
US20100248225A1 (en) * 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
EP2488874A4 (en) * 2009-10-13 2013-08-14 Univ Johns Hopkins BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EA201590041A1 (ru) * 2012-07-03 2015-04-30 Ратиофарм Гмбх Твердая форма холиновой соли вемурафениба
EP3194618B1 (en) * 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법

Also Published As

Publication number Publication date
EP3631017B1 (en) 2022-03-23
CN111315897A (zh) 2020-06-19
IL270787B2 (en) 2023-08-01
CN111315897B (zh) 2024-10-22
ES2920288T3 (es) 2022-08-02
US12399179B2 (en) 2025-08-26
JP2020524524A (ja) 2020-08-20
AU2018273844A1 (en) 2019-12-19
EP3631017A1 (en) 2020-04-08
JP7227964B2 (ja) 2023-02-22
CA3064732A1 (en) 2018-11-29
BR112019024481A2 (pt) 2020-07-14
US20230022236A1 (en) 2023-01-26
AU2018273844B2 (en) 2024-11-14
US20180340934A1 (en) 2018-11-29
KR102763004B1 (ko) 2025-02-04
WO2018217627A1 (en) 2018-11-29
KR20200030034A (ko) 2020-03-19
PL3631017T3 (pl) 2022-09-26
DK3631017T3 (da) 2022-06-20
IL270787B1 (en) 2023-04-01
IL270787A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CL2017002604A1 (es) Sondas duales silenciadoras
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
CY1121341T1 (el) Δοκιμες για την ανιχνευση της παρουσιας ή της ποσοτητας αντισωματος κατα αντισωματος φαρμακου
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
BR112015022763A8 (pt) sensor para detectar um analito
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
CR20150462A (es) Inhibidores de erk y sus usos
BR112015032224A2 (pt) anticorpos anti-fcrh5
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
MX380146B (es) Inhibidores mk2 y usos de los mismos.
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
ECSP13012784A (es) Anticuerpos anti-mesotelina e inmunoconjugados
MX2015017341A (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
BR112015023026A2 (pt) indicador de esterilização para esterilizantes oxidativos e processo para determinar a eficácia de um processo de esterilização utilizando esterilizantes oxidativos
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX390764B (es) Ensayos dispersables en agua